NON SMALL CELL LUNG CARCINOMA
Clinical trials for NON SMALL CELL LUNG CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new NON SMALL CELL LUNG CARCINOMA trials appear
Sign up with your email to follow new studies for NON SMALL CELL LUNG CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental combo for lung cancer shows promise but study cut short
Disease control TerminatedThis phase 2 trial tested a combination of two drugs—NT-I7 and atezolizumab—in people with advanced non-small cell lung cancer that had not been treated before. The goal was to see if the combo could shrink tumors. However, the study was stopped early and only enrolled 33 out of …
Matched conditions: NON SMALL CELL LUNG CARCINOMA
Phase: PHASE2 • Sponsor: NeoImmuneTech • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Experimental cancer pill targets Hard-to-Treat tumors
Disease control TerminatedThis early-stage study tested an experimental oral drug called PRT7732 in people with advanced solid tumors that have a specific genetic mutation (SMARCA4). The main goals were to check safety, find the right dose, and see if the drug could shrink tumors. The study was terminated…
Matched conditions: NON SMALL CELL LUNG CARCINOMA
Phase: PHASE1 • Sponsor: Prelude Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Experimental cancer cocktails show promise, but study halted early
Disease control TerminatedThis early-stage trial tested two drug combinations—TNO155 plus spartalizumab or ribociclib—in 122 adults with advanced solid tumors like lung, head and neck, and colorectal cancers. The goal was to check safety and see if the drugs could slow cancer growth. The study was termina…
Matched conditions: NON SMALL CELL LUNG CARCINOMA
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Experimental cancer pill targets Hard-to-Treat gene mutations
Disease control TerminatedThis early study tested an experimental oral drug called IK-595 in people with advanced solid tumors that have specific RAS or RAF gene mutations. The goal was to check safety, dosing, and early signs of tumor shrinkage. The study was terminated before completion, so full results…
Matched conditions: NON SMALL CELL LUNG CARCINOMA
Phase: PHASE1 • Sponsor: Ikena Oncology • Aim: Disease control
Last updated Jun 26, 2026 19:17 UTC